<DOC>
	<DOCNO>NCT00270894</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness tolerability combination follow medication give every two week HER2 positive breast cancer patient : - trastuzumab ( Herceptin ) - epirubicin ( Ellence ) - cyclophosphamide ( Cytoxan ) - docetaxel ( Taxotere )</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy + Herceptin HER2 Positive Stage II-III Breast Cancer Patients</brief_title>
	<detailed_description>This investigator-initiated , Phase II , non-randomized , single-arm , prospective treatment study . The study consist neoadjuvant treatment period ( week 1 20 ) , surgical evaluation period ( week 20 24 ) , post-surgical/follow-up period ( approximately 3 year ) . Subjects treat outpatient basis . Neoadjuvant therapy consist epirubicin + cyclophosphamide give every 2 week four cycle follow three week break . Subjects receive docetaxel every two week four cycle + trastuzumab ( one load dose ) maintenance dose every 2 week 4 treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Nonpregnant female =/ &gt; 18 year age Noninflammatory breast cancer stage IIA IIIC high risk node negative Core biopsy breast demonstrate invasive cancer document ER/PgR receptor status Normal cardiac function adequate hematologic function Human epidermal growth factor receptor 2 protein ( HER2 ) positive No evidence metastatic disease ECOG Performance Status 0 1 Women childbearing potential must agree use effective contraception treatment least 3 month posttreatment Treated investigational drug within 30 day Uncontrolled intercurrent disease active infection Known sensitivity e. coliderived protein polysorbate 80 Psychiatric illness social situation would limit study compliance Preexisting peripheral neuropathy &gt; Grade 1 Cancer within 5 year screen exception surgically cure nonmelanomatous skin cancer ; insitu carcinoma cervix ; insitu carcinoma breast Bilateral synchronous breast cancer Inflammatory breast cancer Women pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>HER2 positive breast cancer</keyword>
	<keyword>stage II - III breast cancer</keyword>
</DOC>